These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30227480)

  • 1. The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.
    Asahina Y; Tanaka A; Uyama Y; Kuramochi K; Maruyama H
    Ther Innov Regul Sci; 2013 Jan; 47(1):19-22. PubMed ID: 30227480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan.
    Kondo H; Masamune K
    Ther Adv Drug Saf; 2021; 12():20420986211065215. PubMed ID: 34987750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
    Maruyama H; Kondo T
    Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
    Okada K; Koike K; Sawa Y
    Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.
    Moritoyo T
    Clin Ther; 2015 Aug; 37(8):1622-6. PubMed ID: 26342202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
    Masuyama K
    Yakugaku Zasshi; 2013; 133(2):183-6. PubMed ID: 23370511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regulatory Science in the Review of Drugs and Medical Devices].
    Koide A
    Yakugaku Zasshi; 2016; 136(4):557-62. PubMed ID: 27040338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDA's perspective.
    Handa N; Mochizuki S; Fujiwara Y; Shimokawa M; Wakao R; Arai H
    J Artif Organs; 2020 Sep; 23(3):203-206. PubMed ID: 32112156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possibility of Database Research as a Means of Pharmacovigilance in Japan Based on a Comparison with Sertraline Postmarketing Surveillance.
    Hirano Y; Asami Y; Kuribayashi K; Kitazaki S; Yamamoto Y; Fujimoto Y
    Value Health Reg Issues; 2018 May; 15():1-5. PubMed ID: 29474173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Education and training in regulatory science for medical device development.
    Sakuma I
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():3155-8. PubMed ID: 24110397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Information Association (DIA) Japan - 17th Annual Meeting (November 8-10, 2020 - Virtual Meeting).
    Hihara A
    Drugs Today (Barc); 2020 Dec; 56(12):787-793. PubMed ID: 33332485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regulatory authorities expect innovative drug delivery systems (DDS)].
    Mori K
    Yakugaku Zasshi; 2013; 133(1):73-80. PubMed ID: 23292023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment.
    Walker EG; Brumfield M; Compton C; Woosley R
    Ther Innov Regul Sci; 2014 Mar; 48(2):236-245. PubMed ID: 30227514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.
    Sato M; Ochiai Y; Kijima S; Nagai N; Ando Y; Shikano M; Nomura Y
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):413-415. PubMed ID: 28568566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
    Kondo H; Shibatsuji M; Yasuda N
    Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of the last 15 years: from PMDEC to PMDA --looking back at the first stage of the PMDEC].
    Morimoto K; Fujiwara Y; Kawahara A
    Yakushigaku Zasshi; 2011; 46(1):38-50. PubMed ID: 22164689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.